A Phase 2 interventional study of treprostinil diethanolamine and placebo in Systemic Sclerosis and Scleroderma, sponsored by United Therapeutics. Completed at 30 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-28.
Sponsored by United Therapeutics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 165 studies in Scleroderma, Systemic with a site in United States — 40 open to participants now, 52 under way, 6 of them phase 3. Scleroderma, Systemic · United States.
Among the 165 studies in Scleroderma, Systemic with a site in United States, this one is the 27th largest by enrollment of the 142 interventional ones that give a count, is one of 5 that started in 2009, is one of 54 in phase 2, and was the 33rd registered.
613 studies on the registry are indexed under Scleroderma, Systemic; 221 are open to participants now.
Browse Scleroderma, Systemic studies →40 of the 165 studies in Scleroderma, Systemic with a site in United States are open now. Recruiting first, the newest first:
Stephan Grupp MD PhD · Sites in United States
Ages 8–25
Fate Therapeutics · Sites in United States
Ages 18–70
AstraZeneca · Sites in United States, Argentina, Australia and 32 more countries
Ages 5–80
Boehringer Ingelheim · Sites in United States, Argentina, Australia and 42 more countries
Ages 18+
Miltenyi Biomedicine GmbH · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 145 Scleroderma, Systemic studies recruiting now, 83 (57%) set no upper age limit and 49 (34%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
165 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 46 · Phase 2 74 · Phase 3 17 · Phase 4 3
First in 1992; this study’s year is marked. 5 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 148 is above the median of 37 across 449 interventional studies indexed under Scleroderma, Systemic.
Median enrollment 34 across the 142 interventional studies, 67 across the 22 observational. Of the 104 that completed or were terminated, 56 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
69 of 165 have an industry lead sponsor. The 10 most frequent:
United Therapeutics is the lead sponsor of 85 studies on the registry; 8 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.
United Therapeutics has 3 studies filed under Scleroderma, Systemic — fewer than ten, so there is no comparison to draw.
15 of the studies in Scleroderma, Systemic with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05925803Phase 3AstraZenecaDetermine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) | 2027-01-06 |
| NCT06195072Scleroderma Research Foundation, Inc.Platform Clinical Study for Conquering Scleroderma | 2026-11 |
| NCT06375993Adicet TherapeuticsA Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease | 2026-12 |
| NCT04380831City of Hope Medical CenterTBI Using IMRT and Cyclophosphamide Prior to Stem Cell Transplant for the Treatment of Severe Systemic Sclerosis | 2026-12-22 |
| NCT06655155argenxA Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis | 2027-03 |
Add all 15 to your calendar (.ics) → With an account.
Among the 165 studies in Scleroderma, Systemic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the effect of treprostinil diethanolamine (UT-15C) sustained release tablets(compared to placebo) on digital ulcers in patients with scleroderma. Treprostinil diethanolamine is an analog of prostacyclin. Prostacyclin is a naturally occuring substance produced by the cells of blood vessels that inhibits platelet aggregation, induces vasodilation, and suppresses smooth muscle proliferation. Improvement in blood flow in lower limbs and fingers would be anticipated to result in a reduction in ischemic pain, Raynaud's phenomenon and promote healing of digital ulcers and other ischemic wounds.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treprostinil diethanolamine sustained release tablet initiated at 0.25 mg BID and titrated up to a maximum dose of 16 mg BID or the individual's maximum tolerated dose.
Drug: treprostinil diethanolamine
Matching placebo sustained release tablet initiated at 0.25 mg BID and titrated up to a maximum dose of 16 mg BID or the individual's maximum tolerated dose.
Drug: placebo
oral sustained release tablet. Maximum tolerable dose not exceeding 16 mg twice daily (BID)
Net Ulcer Burden
Net ulcer burden was defined as the number of "new" or "active" digital ulcers (DU), plus the number of "indeterminate" DUs at that assessment that have previously been classified as either "active" or "new" at any earlier assessment during the study. A DU was defined as an area with visually discernable depth and a loss of continuity of epithelial coverage, which could be denuded or covered by a scab or necrotic tissue. If denuded, the DU was pronounced "active." If denudation could not be judged because of the presence of scab or necrotic tissue, DU presenting with features, including underlying pain, based on Investigator clinical judgment to be consistent with loss of epithelialization, epidermis, or dermis, and requiring treatment were designated as "active." Otherwise, the DU was pronounced "indeterminate." Only DUs distal to the proximal interphalangeal joints, volar to the equator of the finger, not localized in creases and vascular in origin were assessed.
Time frame: Week 20
Digital Ulcer Pain VAS
Digital ulcer pain was rated on a 100-mm VAS on which subjects were asked to rate their average overall hand pain during the last week. The recorded value was divided by 10, with values ranging from 0.0 (no pain) to 10.0 (unbearable pain), expressed to one decimal.
Time frame: Week 20
Patient Global Assessment of Digital Ulcer Severity VAS
Patients rated their global impression of digital ulcer severity on a 15-cm VAS from scaled 0 (no disease activity) to 100 (very severe disease). The term "severity" was used to measure the extent of disease activity and associated disability or discomfort the patient experienced during the indicated time period.
Time frame: Week 20
Physician Global Assessment of Digital Ulcer Severity VAS
Physicians rated their global impression of digital ulcer severity on a 15-cm VAS from scaled 0 (no disease activity) to 100 (very severe disease). The term "severity" was used to measure the extent of disease activity and associated disability or discomfort the patient experienced during the indicated time period.
Time frame: Week 20
Cochin Hand Function Scale (CHFS)
The CHFS has been demonstrated as a reliable and valid assessment of hand function at the activity level in persons with SSc. It is comprised of 18 questions with possible integer responses of 0 (without difficulty) to 5 (impossible). The CHFS Score is simply the sum of all 18 questions, divided by the number of questions actually answered, multiplied by 18. At least 10 of the 18 questions must have been answered in order for CHFS to be calculated. Therefore, CHFS Score values can range from 0 (least limitation) to 90 (most limitation). A higher score indicates more difficulty in hand function or greater disability.
Time frame: Week 20
Scleroderma Health Assessment Questionnaire (SHAQ)
The SHAQ is a patient self-administered instrument which has been previously validated in SSc and demonstrates meaningful clinical changes in the course of the disease over time. It is comprised of a 20 question instrument pertaining to specific activities with possible integer responses of 0 (without any difficulty) to 3 (unable to do), and five additional scleroderma-specific visual analog scale (VAS) domains (Overall Disease Activity, Raynaud's Phenomenon, Finger Ulcers, Breathing, and Intestinal Problems) with possible values ranging from 0.0 to 15.0. The 20 questions are divided into eight domains. A mean score is calculated for each domain ranging from 0 to 3. A composite HAQ DI score is calculated by dividing the summed domain scores by the number of domains answered. The composite score is reported, falling between 0 and 3 on an ordinal scale. The scores are interpreted as 0 (no impairment in function) to 3 (maximal impairment of function).
Time frame: Week 20
Modified Rodnan Skin Score (mRSS)
The skin thickening was assessed by the Investigator in 17 body areas: fingers, hands, forearms, arms, feet, legs, and thighs (bilaterally) and face, chest, and abdomen (singly). Each area was scored 0-3; 0 representing normal skin and 3 being severe thickening. The mRSS was the sum of the individual skin assessment scores: possible range of 0-51; 0 (no thickening) to 51 (severe thickening in all 17 areas) .
Time frame: Week 20
Short-Form McGill Pain Questionnaire
The SF-MPQ assessment has three component scores: the pain rating index (PRI), a pain visual analogue numerical scale (Pain VAS) and the present pain intensity (PPI). PRI is calculated by summing the responses (0=None to 3=Severe) to the 15 questions describing pain during the previous week and rated on an intensity scale as 0= none, 1= mild, 2= moderate or 3= severe and has possible values ranging from 0 to 45. The Pain VAS is a 100 mm VAS on which subjects were asked to rate pain during the previous week with values ranging from no pain (0.0) to worst possible pain (10.0). The PPI rated pain on a 6-point category scale from 0 (no pain) to 5 (excruciating pain).
Time frame: Week 20
Patient Impression of Change (PIC) Questionnaire
The PIC questionnaire consisted of three Likert items that asked the subject to rate changes in their digital ulcer, Raynaud's phenomenon and disease status since their last visit on a seven-level scale (very much improved, much improved, somewhat improved, same, somewhat worse, much worse and very much worse).
Time frame: Week 20
Short Form 36
Change in patient quality of life was measured by the Medical Outcomes Study 36-Item Short Form Health Survey (SF-36), a self-administered questionnaire covering eight areas: physical function, physical role, bodily pain, general health, vitality, social function, emotional role, and mental health. For each area, the score range from 0 (poorer health status) to 100 (better health status). The SF-36 is one of the most widely used and validated instruments to assess quality of life in patients with systemic illnesses. A decrease (negative change) in a domain score corresponds to deterioration.
Time frame: Week 20
Time to Ulcer Healing- Percentage of Subjects With Complete Healing
A subject was counted as having all ulcers completely healed at the earliest assessment for which all ulcers are designated as "healed" and no new ulcers appeared for the remainder of the trial.
Time frame: Week 20
Time to Ulcer Healing
A subject was counted as having all ulcers completely healed at the earliest assessment for which all ulcers are designated as "healed" and no new ulcers appeared for the remainder of the trial. The time to complete healing of all ulcers were calculated as the number of days from randomization to the date of these respective assessments, provided that complete healing was achieved during the study.
Time frame: Week 20
Subjects were recruited across 32 clinical trial sites in the US, Canada and UK experienced in the treatment of systemic sclerosis (SSc) and capable of conducting the trial according to ICH GCP guidance. Subjects were recruited between April 2009 and October 2010.
| Milestone | Placebo | Treprostinil Diethanolamine |
|---|---|---|
| Started | 76 | 72 |
| Completed | 65 | 59 |
| Not completed | 11 | 13 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: Adverse event | 7 | 9 |
| Withdrew: Protocol violation | 2 | 2 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Lack of efficacy | 1 | 1 |
Net ulcer burden was defined as the number of "new" or "active" digital ulcers (DU), plus the number of "indeterminate" DUs at that assessment that have previously been classified as either "active" or "new" at any earlier assessment during the study. A DU was defined as an area with visually discernable depth and a loss of continuity of epithelial coverage, which could be denuded or covered by a scab or necrotic tissue. If denuded, the DU was pronounced "active." If denudation could not be judged because of the presence of scab or necrotic tissue, DU presenting with features, including underlying pain, based on Investigator clinical judgment to be consistent with loss of epithelialization, epidermis, or dermis, and requiring treatment were designated as "active." Otherwise, the DU was pronounced "indeterminate." Only DUs distal to the proximal interphalangeal joints, volar to the equator of the finger, not localized in creases and vascular in origin were assessed.
| ulcers | Placebo | Treprostinil Diethanolamine |
|---|---|---|
| Baseline | 1.0 (1.0 to 2.0) | 2.0 (1.0 to 2.0) |
| Change at Week 20 | 0.0 (-1.0 to 1.0) | -1.0 (-1.0 to 0.0) |
Digital ulcer pain was rated on a 100-mm VAS on which subjects were asked to rate their average overall hand pain during the last week. The recorded value was divided by 10, with values ranging from 0.0 (no pain) to 10.0 (unbearable pain), expressed to one decimal.
| units on a scale | Placebo | Treprostinil Diethanolamine |
|---|---|---|
| Baseline | 4.85 (2.75 to 6.75) | 6.00 (2.80 to 7.70) |
| Change at Week 20 | -1.05 (-3.20 to 0.10) | -1.45 (-4.60 to 0.00) |
Patients rated their global impression of digital ulcer severity on a 15-cm VAS from scaled 0 (no disease activity) to 100 (very severe disease). The term "severity" was used to measure the extent of disease activity and associated disability or discomfort the patient experienced during the indicated time period.
| units on a scale | Placebo | Treprostinil Diethanolamine |
|---|---|---|
| Baseline | 57.0 (29.3 to 79.7) | 67.0 (34.7 to 78.0) |
| Change at Week 20 | -24.0 (-43.0 to 0.0) | -24.3 (-63.3 to -3.3) |
Physicians rated their global impression of digital ulcer severity on a 15-cm VAS from scaled 0 (no disease activity) to 100 (very severe disease). The term "severity" was used to measure the extent of disease activity and associated disability or discomfort the patient experienced during the indicated time period.
| units on a scale | Placebo | Treprostinil Diethanolamine |
|---|---|---|
| Baseline | 44.7 (26.0 to 63.3) | 47.3 (31.3 to 66.7) |
| Change at Week 20 | -13.3 (-31.3 to -1.3) | -26.7 (-43.3 to -5.3) |
The CHFS has been demonstrated as a reliable and valid assessment of hand function at the activity level in persons with SSc. It is comprised of 18 questions with possible integer responses of 0 (without difficulty) to 5 (impossible). The CHFS Score is simply the sum of all 18 questions, divided by the number of questions actually answered, multiplied by 18. At least 10 of the 18 questions must have been answered in order for CHFS to be calculated. Therefore, CHFS Score values can range from 0 (least limitation) to 90 (most limitation). A higher score indicates more difficulty in hand function or greater disability.
| units on a scale | Placebo | Treprostinil Diethanolamine |
|---|---|---|
| Baseline | 18.5 (5.0 to 29.5) | 24.0 (11.0 to 37.0) |
| Week 20 | 19.0 (4.0 to 33.5) | 21.0 (8.0 to 35.0) |
The SHAQ is a patient self-administered instrument which has been previously validated in SSc and demonstrates meaningful clinical changes in the course of the disease over time. It is comprised of a 20 question instrument pertaining to specific activities with possible integer responses of 0 (without any difficulty) to 3 (unable to do), and five additional scleroderma-specific visual analog scale (VAS) domains (Overall Disease Activity, Raynaud's Phenomenon, Finger Ulcers, Breathing, and Intestinal Problems) with possible values ranging from 0.0 to 15.0. The 20 questions are divided into eight domains. A mean score is calculated for each domain ranging from 0 to 3. A composite HAQ DI score is calculated by dividing the summed domain scores by the number of domains answered. The composite score is reported, falling between 0 and 3 on an ordinal scale. The scores are interpreted as 0 (no impairment in function) to 3 (maximal impairment of function).
| units on a scale | Placebo | Treprostinil Diethanolamine |
|---|---|---|
| Dressing & Grooming Score: Baseline (76/71) | 0.50 (0.00 to 1.00) | 1.00 (0.50 to 1.50) |
| Dressing&Grooming Score:Change at Week 20 | 0.00 (0.00 to 0.00) | 0.00 (-0.50 to 0.00) |
| Arising Score: Baseline (76/71) | 0.00 (0.00 to 1.00) | 0.00 (0.00 to 1.00) |
| Arising Score: Change at Week 20 | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) |
| Eating Score: Baseline (76/71) | 0.67 (0.00 to 1.00) | 0.67 (0.33 to 1.00) |
| Eating Score: Change at Week 20 | 0.00 (-1.17 to 0.08) | 0.00 (-0.33 to 0.17) |
| Walking Score: Baseline (76/71) | 0.00 (0.00 to 0.50) | 0.00 (0.00 to 0.50) |
| Walking Score: Change at Week 20 | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) |
| Hygiene Score: Baseline (76/68) | 0.00 (0.00 to 0.67) | 0.33 (0.00 to 0.67) |
| Hygiene Score: Change at Week 20 | 0.00 (0.00 to 0.33) | 0.00 (0.00 to 0.33) |
| Reach Score: Baseline (76/68) | 0.00 (0.00 to 1.00) | 0.50 (0.00 to 1.00) |
| Reach Score: Change at Week 20 | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) |
| Grip Score: Baseline (76/68) | 0.33 (0.00 to 0.67) | 0.33 (0.17 to 1.00) |
| Grip Score: Change at Week 20 | 0.00 (0.00 to 0.33) | 0.00 (-0.33 to 0.00) |
| Activity Score: Baseline (76/68) | 0.33 (0.00 to 1.00) | 0.67 (0.00 to 1.00) |
| Activity Score: Change at Week 20 | 0.00 (0.00 to 0.33) | 0.00 (0.00 to 0.17) |
| HAQ Aggregate Score: Baseline (76/68) | 0.34 (0.10 to 0.77) | 0.53 (0.26 to 0.81) |
| HAQ Aggregate Score: Change at Week 20 | 0.00 (-0.07 to 0.13) | -0.03 (-0.16 to 0.12) |
| Hand Function Aggregate Score: Baseline (76/68) | 0.39 (0.11 to 0.69) | 0.56 (0.28 to 0.86) |
| Hand Function Aggregate Score: Change at Week 20 | 0.00 (-0.06 to 0.17) | 0.00 (-0.22 to 0.11) |
| Raynaud's Phenomenon VAS Score: Baseline (75/71) | 0.12 (0.00 to 0.64) | 0.18 (0.02 to 0.80) |
| Raynaud's Phenomenon VAS Score: Change at Week 20 | 0.00 (-0.14 to 0.08) | 0.00 (-0.14 to 0.14) |
| Intestinal Problems VAS Score: Baseline (75/70) | 0.20 (0.00 to 0.70) | 0.11 (0.02 to 0.62) |
| Intestinal Problems VAS Score: Change at Week 20 | 0.00 (-0.10 to 0.24) | 0.11 (-0.02 to 0.72) |
| Digital Ulcer VAS Score: Baseline (76/71) | 1.43 (0.49 to 2.09) | 1.50 (0.68 to 2.28) |
| Digital Ulcer VAS Score: Change at Week 20 | -0.34 (-0.92 to 0.00) | -0.56 (-1.36 to 0.00) |
| Breathing Problems VAS Score: Baseline (76/71) | 1.54 (0.95 to 2.31) | 2.16 (0.96 to 2.54) |
| Breathing Problems VAS Score: Change at Week 20 | -0.50 (-1.15 to 0.00) | -0.84 (-2.14 to -0.20) |
| Pain VAS Score: Baseline (76/69) | 1.27 (0.57 to 1.91) | 1.54 (0.54 to 2.16) |
| Pain VAS Score: Change at Week 20 | -0.26 (-0.93 to 0.11) | -0.34 (-1.44 to 0.00) |
| Overall Disease VAS Score: Baseline (76/71) | 1.22 (0.67 to 1.87) | 1.52 (0.74 to 2.12) |
| Overall Disease VAS Score: Change at Week 20 | -0.18 (-0.60 to 0.04) | -0.32 (-1.00 to 0.10) |
The skin thickening was assessed by the Investigator in 17 body areas: fingers, hands, forearms, arms, feet, legs, and thighs (bilaterally) and face, chest, and abdomen (singly). Each area was scored 0-3; 0 representing normal skin and 3 being severe thickening. The mRSS was the sum of the individual skin assessment scores: possible range of 0-51; 0 (no thickening) to 51 (severe thickening in all 17 areas) .
| units on a scale | Placebo | Treprostinil Diethanolamine |
|---|---|---|
| Baseline | 6.0 (3.0 to 12.0) | 8.0 (5.0 to 14.0) |
| Week 20 | 6.0 (3.0 to 12.0) | 6.0 (3.0 to 15.0) |
The SF-MPQ assessment has three component scores: the pain rating index (PRI), a pain visual analogue numerical scale (Pain VAS) and the present pain intensity (PPI). PRI is calculated by summing the responses (0=None to 3=Severe) to the 15 questions describing pain during the previous week and rated on an intensity scale as 0= none, 1= mild, 2= moderate or 3= severe and has possible values ranging from 0 to 45. The Pain VAS is a 100 mm VAS on which subjects were asked to rate pain during the previous week with values ranging from no pain (0.0) to worst possible pain (10.0). The PPI rated pain on a 6-point category scale from 0 (no pain) to 5 (excruciating pain).
| units on a scale | Placebo | Treprostinil Diethanolamine |
|---|---|---|
| Total Pain Rating Index Score Change at Week 20 | -4.0 (-8.0 to 1.0) | -3.0 (-12.0 to 0.0) |
| Pain VAS Score Change at Week 20 | -0.6 (-2.9 to 0.3) | -1.1 (-4.4 to 0.2) |
| Present Pain Intensity Score Change at Week 20 | 0.0 (-1.0 to 0.0) | -1.0 (-1.0 to 0.0) |
The PIC questionnaire consisted of three Likert items that asked the subject to rate changes in their digital ulcer, Raynaud's phenomenon and disease status since their last visit on a seven-level scale (very much improved, much improved, somewhat improved, same, somewhat worse, much worse and very much worse).
| participants | Placebo- Digital Ulcer Response | Treprostinil Diethanolamine- Digital Ulcer Response | Placebo- Raynaud's Phenomenon Response | Treprostinil Diethanolamine- Raynaud's Phenomenon Response | Placebo- Overall Disease Status Response | Treprostinil Diethanolamine- Overall Disease Status Response |
|---|---|---|---|---|---|---|
| Very Much Improved | 5 | 9 | 0 | 3 | 0 | 3 |
| Much Improved | 11 | 15 | 4 | 12 | 5 | 17 |
| Somewhat Improved | 20 | 14 | 12 | 20 | 22 | 13 |
| Same | 24 | 21 | 40 | 30 | 30 | 27 |
| Somewhat Worse | 14 | 8 | 17 | 4 | 18 | 10 |
| Much Worse | 1 | 3 | 1 | 1 | 0 | 0 |
| Very Much Worse | 1 | 1 | 2 | 1 | 1 | 1 |
Change in patient quality of life was measured by the Medical Outcomes Study 36-Item Short Form Health Survey (SF-36), a self-administered questionnaire covering eight areas: physical function, physical role, bodily pain, general health, vitality, social function, emotional role, and mental health. For each area, the score range from 0 (poorer health status) to 100 (better health status). The SF-36 is one of the most widely used and validated instruments to assess quality of life in patients with systemic illnesses. A decrease (negative change) in a domain score corresponds to deterioration.
| units on a scale | Placebo | Treprostinil Diethanolamine |
|---|---|---|
| Physical Component: Baseline | 55.0 (39.5 to 67.5) | 50.7 (35.1 to 62.9) |
| Physical Component: Change at Week 20 | 2.8 (-5.3 to 10.9) | 3.8 (-2.1 to 10.3) |
| Physical Functioning: Baseline | 62.5 (30.0 to 80.0) | 60.0 (35.0 to 75.0) |
| Physical Functioning: Change at Week 20 | 0.0 (-5.0 to 10.0) | 0.0 (-10.0 to 10.0) |
| Role-Physical: Baseline | 54.4 (37.5 to 72.5) | 50.0 (25.0 to 70.0) |
| Role-Physical: Change at Week 20 | 0.0 (-10.0 to 17.5) | 0.0 (0.0 to 22.5) |
| Bodily Pain: Baseline | 57.5 (33.8 to 67.5) | 45.0 (32.5 to 75.0) |
| Bodily Pain: Change at Week 20 | 10.0 (-5.0 to 21.3) | 10.0 (-2.5 to 22.5) |
| General Health: Baseline | 42.0 (34.0 to 65.0) | 45.0 (30.0 to 63.0) |
| General Health: Change at Week 20 | 0.0 (-9.5 to 5.0) | 0.0 (-5.0 to 6.0) |
| Mental Component: Baseline | 68.3 (54.1 to 77.4) | 64.2 (49.2 to 76.1) |
| Mental Component: Change at Week 20 | 2.6 (-8.6 to 11.0) | 4.0 (-4.0 to 15.7) |
| Vitality: Baseline (75/71) | 50.0 (31.3 to 62.5) | 43.8 (25.0 to 61.3) |
| Vitality: Change at Week 20 | 0.0 (-6.3 to 7.5) | 1.3 (-6.3 to 17.5) |
| Social Functioning: Baseline | 72.5 (50.0 to 87.5) | 62.5 (50.0 to 85.0) |
| Social Functioning: Change at Week 20 | 0.0 (-12.5 to 13.8) | 10.0 (0.0 to 22.5) |
| Role-Emotional: Baseline | 70.0 (60.8 to 95.0) | 80.0 (50.0 to 100.0) |
| Role-Emotional: Change at Week 20 | 0.0 (-5.8 to 11.7) | 0.0 (-1.7 to 13.3) |
| Mental Health: Baseline (75/71) | 69.0 (52.0 to 84.0) | 64.0 (54.0 to 79.0) |
| Mental Health: Change at Week 20 | 2.0 (-6.0 to 11.0) | 3.0 (-5.0 to 16.0) |
A subject was counted as having all ulcers completely healed at the earliest assessment for which all ulcers are designated as "healed" and no new ulcers appeared for the remainder of the trial.
| percentage of participants | Placebo | Treprostinil Diethanolamine |
|---|---|---|
| Cardinal Ulcer Healed | 61 | 62 |
| All Ulcers Healed | 41 | 49 |
A subject was counted as having all ulcers completely healed at the earliest assessment for which all ulcers are designated as "healed" and no new ulcers appeared for the remainder of the trial. The time to complete healing of all ulcers were calculated as the number of days from randomization to the date of these respective assessments, provided that complete healing was achieved during the study.
| days | Placebo | Treprostinil Diethanolamine |
|---|---|---|
| Time to Cardinal Ulcer Healing | 83.2 ± 37.9 | 76.3 ± 35 |
| Time to All Ulcers Healed | 96.7 ± 39.7 | 90.2 ± 35.6 |
Collected over 20 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/76 (0%) | 4/76 (5.3%) | 74/76 (97.4%) |
| Treprostinil Diethanolamine | 0/71 (0%) | 9/71 (12.7%) | 71/71 (100%) |
| Event | Placebo | Treprostinil Diethanolamine |
|---|---|---|
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 0/76 | 2/71 |
| PneumoniaInfections and infestations | 1/76 | 1/71 |
| GastroenteritisInfections and infestations | 0/76 | 1/71 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/76 | 1/71 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 0/76 | 1/71 |
| VomitingGastrointestinal disorders | 1/76 | 1/71 |
| ConstipationGastrointestinal disorders | 0/76 | 1/71 |
| Erosive oesophagitisGastrointestinal disorders | 0/76 | 1/71 |
| Gastric ulcer haemorrhageGastrointestinal disorders | 0/76 | 1/71 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/76 | 1/71 |
| Event | Placebo | Treprostinil Diethanolamine |
|---|---|---|
| HeadacheNervous system disorders | 32/76 | 52/71 |
| NauseaGastrointestinal disorders | 14/76 | 42/71 |
| DiarrhoeaGastrointestinal disorders | 16/76 | 40/71 |
| Pain in jawMusculoskeletal and connective tissue disorders | 4/76 | 17/71 |
| FlushingVascular disorders | 3/76 | 17/71 |
| FatigueGeneral disorders | 15/76 | 16/71 |
| Infected skin ulcerSkin and subcutaneous tissue disorders | 10/76 | 13/71 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 12/76 | 12/71 |
| VomitingGastrointestinal disorders | 4/76 | 12/71 |
| PainGeneral disorders | 1/76 | 12/71 |
Baseline demographics and characteristics were summarized for subjects who received at least one dose of study drug. One subject in the treprostinil diethanolamine treatment group was randomized, withdrew consent and exited the study prior to taking any study medication and is not included in the summary.
| Age, Continuous(years) | Placebo | Treprostinil Diethanolamine | Total |
|---|---|---|---|
| Mean | 47.8 (20 to 74) | 49.8 (19 to 82) | 48.8 (19 to 82) |
| Sex: Female, Male(Participants) | Placebo | Treprostinil Diethanolamine | Total |
|---|---|---|---|
| Female | 55 | 54 | 109 |
| Male | 21 | 17 | 38 |
| Race/Ethnicity, Customized(participants) | Placebo | Treprostinil Diethanolamine | Total |
|---|---|---|---|
| Asian | 3 | 4 | 7 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 10 | 7 | 17 |
| White | 62 | 59 | 121 |
| Unknown or Not Reported | 1 | 1 | 2 |
| SSc Classification(participants) | Placebo | Treprostinil Diethanolamine | Total |
|---|---|---|---|
| Limited | 55 | 40 | 95 |
| Diffuse | 21 | 31 | 52 |
| Years since SSc diagnosis(years) | Placebo | Treprostinil Diethanolamine | Total |
|---|---|---|---|
| Mean | 10.7 (0 to 30) | 10.3 (0 to 35) | 10.5 (0 to 35) |
The record gives a start of May 2009, a primary completion of Mar 2011 and a completion of Jul 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2014, 3 years after primary completion. A results delay was requested in Feb 2013.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Treprostinil